Thermo Fisher Scientific exceeded Q2 2025 revenue and earnings estimates, driven by strong growth in life sciences solutions and laboratory products segments. The company increased full-year revenue guidance to $43.6–44.2 billion and adjusted EPS to $22.22–22.84, citing ongoing cost management and easing US-China tariff tensions. CEO Marc Casper highlighted solid execution despite macroeconomic pressures. CFO Stephen Williamson announced plans to retire in 2026, with Jim Meyer named successor. Shares surged over 10% following the earnings release.